Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)

BACKGROUND: The DNA damaging platinum salts have been explored in the treatment of triple negative breast cancer (TNBC) based on preclinical, and, more recently, clinical evidence of specific susceptibility of TNBC to these agents. Despite the increased toxicity, treatment intensification with polyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, Arlindo R., Metzger-Filho, Otto, Sarmento, Roberta M. B., Bines, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787778/
https://www.ncbi.nlm.nih.gov/pubmed/29416986
http://dx.doi.org/10.3389/fonc.2017.00329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787778/
https://www.ncbi.nlm.nih.gov/pubmed/29416986
http://dx.doi.org/10.3389/fonc.2017.00329

Ejemplares similares